Results 201 to 210 of about 81,917 (261)

Rapid response to BRAF/MEK inhibitor therapy within 2 weeks for high-grade glioma with leptomeningeal metastasis: illustrative case. [PDF]

J Neurosurg Case Lessons
Kawaguchi Y, Hana T, Hasegawa H, Murakami C, Higashi M, Hanakita S.   +5 more
europepmc   +1 more source

The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinoma. [PDF]

Sci Rep
Katt WP, Balkman CE, Butler SD, Byron M, Carney PC, Todd-Donato AB, Drozd ME, Duhamel GE, Evans JM, Fiani N, Ford JC, Grenier JK, Hayward JJ, Heikinheimo K, Hume KR, Moore ES, Puri R, Sylvester SR, Warshaw SL, Webb SM, White AC, Wright AL, Cerione RA, Peralta S.   +23 more
europepmc   +1 more source

Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study. [PDF]

Cancer Immunol Immunother
Beckmann M, Schlüter J, Erdmann M, Kramer R, Cunningham S, Hackstein H, Zimmermann R, Heinzerling L.   +7 more
europepmc   +1 more source

Elevated lactate dehydrogenase in adjuvant BRAF and MEK inhibitor therapy does not have diagnostic significance in detecting melanoma recurrence. [PDF]

Contemp Oncol (Pozn)
Galus Ł, Tusień-Małecka D, Mackiewicz J.   +2 more
europepmc   +1 more source

Vitamin C and MEK Inhibitor PD0325901 Synergistically Promote Oligodendrocytes Generation by Promoting DNA Demethylation. [PDF]

Molecules
Ren X, Yang Y, Wang M, Yuan Q, Suo N, Xie X.   +5 more
europepmc   +1 more source

Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical Trial.

JAMA Dermatol
Gross AM, Reid OH, Baldwin LA, Cannon A, Choo-Wosoba H, Steinberg SM, Lobbous M, Wolters PL, Pichard DC, Tibery CM, Dombi E, Derdak J, Widemann BC, Korf BR.   +13 more
europepmc   +1 more source

Allosteric MEK Inhibitors Act on BRAF/MEK Complexes to Block MEK Activation

Proceedings of the National Academy of Sciences of the United States of America, 2021
Significance Drugs that inhibit specific kinases now represent one of the main classes of targeted therapies. A majority of drug development efforts in this space focus on a given kinase in isolation as the target. However, our work demonstrates that in the context of the RAF/MEK/ERK pathway, the relevant target for compounds ...
Eunyoung Park, Gonzalo L Gonzalez-Del Pino, Kunhua Li   +2 more
exaly   +4 more sources